AES 2021 Symposium Summary of Results from the "X-TOLE" Study FRIDAY, DECEMBER 3, 2021 NASDAQ: XENE www.xenon-pharma.com XEN1101 Next-Gen KV7 Channel Opener ▪ Only-in-class KV7 potassium channel modulator to treat adult focal seizures ▪ Novel MOA for rational polypharmacy ▪ Designed to address limitations of first-gen KV7 modulator, ezogabine • Higher in vitro and in vivo potency • PK TID → QD • Lacks the chemical properties that could form pigmented dimers ▪ Improved seizure reduction ▪ Potential to treat ...